Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.
暂无分享,去创建一个
A. Branch | R. Dhanasekaran | C. Murphy | A. Duarte-Rojo | A. Singal | M. Schwartz | R. Wong | L. Kulik | J. Feld | H. Samant | M. Leise | N. Parikh | Janice H. Jou | T. Tran | A. Said | A. Rangnekar | P. Jalal | C. Frenette | S. Satapathy | K. Bhamidimarri | A. Pillai | Chanda Ho | M. Hoteit | N. Rich | N. Mehta | R. Salgia | Omobonike O. Oloruntoba | S. Eswaran | S. Scaglione | P. Mantry | B. John | Avegail Flores | M. Odewole | J. Guy | R. Mitrani | V. R. Konjeti | Jesse J. Xie | M. Volk | U. Rahim | S. Misra | A. Huang | Sasank Nakka | Wassim Noureddine | A. Dao | Kevin M. Nelson | K. Delarosa | M. Mavuram | Binu V. John
[1] A. Singal,et al. Systematic review with meta‐analysis: recurrence of hepatocellular carcinoma following direct‐acting antiviral therapy , 2018, Alimentary pharmacology & therapeutics.
[2] L. N. Valenti,et al. IFN-free DAA treatment of cirrhotic HCV patients with or without history of HCC: A multicenter prospective trial in Italy , 2018 .
[3] G. Heinze,et al. An unjustified benefit: immortal time bias in the analysis of time‐dependent events , 2018, Transplant international : official journal of the European Society for Organ Transplantation.
[4] C. Sirlin,et al. Imaging for the diagnosis of hepatocellular carcinoma: A systematic review and meta‐analysis , 2018, Hepatology.
[5] H. Nomura,et al. Short‐term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct‐acting anti‐viral treatment , 2018, Alimentary pharmacology & therapeutics.
[6] M. Abecassis,et al. AASLD guidelines for the treatment of hepatocellular carcinoma , 2018, Hepatology.
[7] P. Stang,et al. Methods for time‐varying exposure related problems in pharmacoepidemiology: An overview , 2017, Pharmacoepidemiology and drug safety.
[8] G. Dore,et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. , 2017, Journal of hepatology.
[9] T. Berg,et al. Hepatocellular carcinoma recurrence after direct antiviral agent treatment: A European multicentre study. , 2017, Journal of hepatology.
[10] S. Asch,et al. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. , 2017, Gastroenterology.
[11] C. Nam,et al. Statistical methods for elimination of guarantee-time bias in cohort studies: a simulation study , 2017, BMC Medical Research Methodology.
[12] G. Cabibbo,et al. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct‐acting antivirals? A prospective multicentre study , 2017, Alimentary pharmacology & therapeutics.
[13] A. Gasbarrini,et al. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. , 2017, Journal of hepatology.
[14] D. Goldberg,et al. Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality. , 2017, Gastroenterology.
[15] J. Bruix,et al. Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure? , 2017, Seminars in Liver Disease.
[16] G. Cordone,et al. Hepatocellular carcinoma recurrence rate in HCV infected patients treated with direct antiviral agents. A single center experience , 2017 .
[17] M. Kurosaki,et al. Direct acting antivirals did not increase early recurrences after curative treatment of HCV related hepatocellular carcinoma in comparison with IFN-based treatment , 2017 .
[18] G. Ioannou,et al. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. , 2017, Journal of hepatology.
[19] K. Koike,et al. The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma. , 2016, Journal of hepatology.
[20] L. Bolondi,et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. , 2016, Journal of hepatology.
[21] M. Colombo,et al. Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution. , 2016, Journal of hepatology.
[22] M. Schwartz,et al. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. , 2015, Annals of surgery.
[23] D. Sze,et al. Optimal imaging surveillance schedules after liver-directed therapy for hepatocellular carcinoma. , 2015, Journal of vascular and interventional radiology : JVIR.
[24] A. Moorman,et al. Hepatitis C in the United States. , 2013, The New England journal of medicine.
[25] J. Marrero,et al. Establishment of a Multidisciplinary Hepatocellular Carcinoma Clinic is Associated with Improved Clinical Outcome , 2013, Annals of Surgical Oncology.
[26] H. El‐Serag,et al. Epidemiology of viral hepatitis and hepatocellular carcinoma. , 2012, Gastroenterology.
[27] Ryosuke Tateishi,et al. nature publishing group ORIGINAL CONTRIBUTIONS 569 CME Radiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic Factors LIVER , 2022 .
[28] William M. Lee,et al. Utilization of Hepatocellular Carcinoma Surveillance Among American Patients: A Systematic Review , 2012, Journal of General Internal Medicine.
[29] M. Volk,et al. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.